Please login to the form below
renal cell carcinoma
This page shows the latest renal cell carcinoma news and features for those working in and with pharma, biotech and healthcare.
BMS claims rapid FDA nod for Opdivo plus Yervoy in kidney cancer
The US regulator has given the green light to PD-1 inhibitor Opdivo (nivolumab) and CTLA4 inhibitor Yervoy (ipilimumab) as an initial treatment for advanced renal cell carcinoma (RCC) patients on ... in several other tumour types including non-small cell
Latest news
-
Pfizer’s plans for Inlyta go awry with failed adjuvant trial
Pfizer’s hopes of reversing the decline of its renal cell carcinoma (RCC) treatment Inlyta have taken a knock with a failed phase III trial in patients with less advanced disease.
-
$5.76bn deal puts Merck closer to Eisai and fast-growing Lenvima
First approved in 2015 for refractory thyroid cancer, Lenvima has subsequently been given the nod as a second-line treatment for renal cell carcinoma in combination with everolimus and has been ... submitted for approval for hepatocellular carcinoma, a
-
BMS pens massive $3.6bn deal for Nektar cancer immunotherapy
including melanoma, renal cell carcinoma, non-small-cell lung cancer, bladder cancer and triple-negative breast cancer. ... NKTR-214 is a CD122-biased agonist designed to stimulate the patient's own immune system to fight cancer, working to expand T cell
-
NICE backs EUSA's RCC treatment Fotivda
Lee Morley, chief executive officer for EUSA Pharma, said: “We are very pleased that NICE are recommending the use of Fotivda for the first-line treatment of advanced renal cell carcinoma ... cases. EUSA licenced Fotivda from Aveo Pharmaceuticals back
-
Roche unveils data for Tecentriq/Avastin combo in kidney cancer
The trial involved previously untreated patients with inoperable locally-advanced or metastatic renal cell carcinoma (RCC) whose tumours express the PD-L1 biomarker and will be presented at the American Society ... Last year, the IMpower150 trial of
More from news
Approximately 5 fully matching, plus 127 partially matching documents found.
Latest Intelligence
-
Accelerating innovation
Although marketed as the orphan drug Cometriq for thyroid neoplasms, it’s as Cabometyx in renal cell carcinoma (RCC) where the firm views real potential.
-
Charting a course for expansion
Its first US approval came in April for second-line treatment of renal cell carcinoma (RCC), a prevalent and difficult-to-diagnose cancer, with European regulators giving it the green light ... It showed that Cabometyx can decrease the rate of disease
-
Deal Watch March 2016
Collaboration – discovery, development &commercialisation. $965. Exelixis/ Ipsen. Cabozantinib (Renal Cell Carcinoma, Hepatocellular Carcinoma, other indications) and Cometriq (medullary thyroid cancer).
-
Deal Watch December 2015
510. SQZ Biotech (US). Roche. Collaboration, licence. B cell engineering platform to discover oncology targets . ... 405. Aveo (US). EUSA. Collaboration, licence. Pre-registration tivozanib for renal cell carcinoma.
-
Pharma deals during April 2014
Additional GSK products include the VEGFR inhibitor, Votrient (renal cell carcinoma), Tykerb (HER2 metastatic breast cancer), Arzerra (chronic lymphocytic leukaemia) and Promacta (thrombocytopenia). ... This was largely driven by the phase 2 autologous
More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.
Latest appointments
-
AVEO appoints Nikhil Mehta as its senior VP, regulatory and quality assurance
and oncology that we believe will be invaluable as we plan and advance our US registration strategy for tivozanib as a potential treatment for renal cell carcinoma.”.
-
CytomX appoints Rachel Humphrey chief medical officer
Humphrey also spent time at Bayer where she oversaw the early and late stage clinical development of the renal cell carcinoma treatment Nexavar (sorafenib).
-
Bayer’s former oncology head Robert Rosen joins AP Pharma
During this time, he led the launch of Nexavar (sorafenib), which made more than $1bn last year, for the treatment of renal cell carcinoma and hepatocellular carcinoma.
-
Former Bayer oncology head Robert Rosen joins AP Pharma's board
Former Bayer oncology head Robert Rosen joins AP Pharma's board. While at Bayer Rosen led launch of Nexavar for renal cell carcinoma and hepatocellular carcinoma. ... Rosen was in charge of Bayer's oncology efforts from 2005 to 2011, where he led the
More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.
Latest from PMHub
-
A stumble, but not a fall – what’s next for Opdivo?
and renal cell carcinoma (kidney cancer). ... Back then, the UK’ s cost-effectiveness watchdog NICE deemed Opdivo too pricey for renal cell carcinoma when taking into account the availability of Pfizer's Inlyta at a markedly lower
-
CABOSUN trial of cabozantinib – could it change how we treat frontline renal-cell carcinoma?
CABOSUN trial of cabozantinib – could it change how we treat frontline renal-cell carcinoma? ... In the CABOSUN trial, cabozantinib was compared to sunitinib in treatment naive poor and intermediate risk renal-cell carcinoma (RCC) patients.
More from PMHub
Approximately 1 fully matching, plus 1 partially matching documents found.
Featured jobs
- Project Manager, Medical Communications, London
-
Excellent Salary
- Senior Medical Writer, Medical Communications, Relocate to Cardi...
-
Excellent Salary
-
Scientific Director
-
Great salary and bebefits
- Senior Account Manager – Med Comms – Kent
-
Salary TBC
- FREELANCE Account Manager – Creative Healthcare Advertising – Lo...
-
SUPERB DAY RATES AVAILABLE
-
Senior Medical Writer
-
Great salary and benefits
- FREELANCE OPPORTUNITIES!!!!! Medical Education - Healthcare Adve...
-
EXCELLENT DAY RATES AVAILABLE
-
Senior Programme Executive
-
Salary TBC
- Principal Medical Writer, Medical Communications, Relocate to Ca...
-
Excellent Salary
-
Senior Medical Writer
-
Great salary and bebefits
- Account Manager – Med Comms – London
-
Salary TBC
- Senior / Principal Regulatory Writer – Home Working - UK or US
-
HIGHLEY COMPETATIVE SALARY, BONUS &BENEFITS
- Project Manager, Medical Communications, Oxford
-
Excellent Salary
-
Account Manager, Healthcare PR
-
£40, 000 – £42, 000 great benefits and bonuses
- Editorial Team Leader or Scientific Director
-
£50, 000 - £55, 000 benefits
- Senior Account Director, Healthcare Brand Communications, London
-
Excellent Package
- Editor – Medical Education Agency – Bucks
-
Salary TBC
- Senior Account Manager / Account Director
-
Great salary and bebefits
Subscribe to our email news alerts
No results were found
- P&G agrees $4.2bn buy of Merck KGaA’s consumer health unit
- Publicis LifeBrands Team win UK young Cannes Lions competition
- Sobi poaches Pfizer’s Fredrick Wetterlundh
- Rigel and Ultragenyx claim approvals for rare drugs
- VCCP Health strengthens client service team
- Is agile working benefiting the employee or the organisation?
PMHub
Rainmaker Healthcare Communications
Rainmaker is an independent, award-winning communications agency with offices in London and Atlanta. Our experience across pharmaceuticals, generics, OTC, medical...
Latest intelligence
- The threat of antimicrobial resistance
- Why this issue is such a fundamental challenge...
- Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
- Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
- Unique forum will unite NHS and industry to drive innovation
- HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...
Quick links
Infographics
